These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Sep 19, 2013
Agenus Inc. (Nasdaq: AGEN) today announced that it received additional demand for its previously announced registered direct offering and today accepted additional commitments from existing and...
Sep 18, 2013Agenus to Participate in Brain Cancer Vaccine and Immunotherapy Discussion on September 23rd Webcast
Agenus Inc. (Nasdaq: AGEN) today announced that Dr. Garo Armen, chairman and CEO of Agenus, will participate in a webcast, titled "Glioblastoma – Brain Cancer: The Next Generation of Therapies,"...
Sep 18, 2013
Agenus Inc. (Nasdaq: AGEN) today announced that it has received commitments from institutional investors to purchase an aggregate of approximately $6.5 million of its common stock at the market....
Sep 17, 2013Agenus Reports Positive Follow-on Phase 2 Results for Brain Cancer Vaccine in Newly Diagnosed PatientsAnalysis of patients treated with Prophage Series G-100 (HSPPC-96) show improvement in progression free survival and overall survival versus standard of care
Agenus Inc. (Nasdaq: AGEN) today announced that a recent analysis from a Phase 2 trial in patients with newly diagnosed glioblastoma multiforme (GBM) treated with Prophage Series G-100 (HSPPC-96)...
Sep 5, 2013In Line with Independent Data Monitoring Committee’s (IDMC) Unanimous Recommendation, GSK will Continue Study Until Second Co-primary Endpoint is Assessed
Agenus Inc. (Nasdaq: AGEN) today announced that GlaxoSmithKline’s (NYSE: GSK) DERMAi study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3 cancer immunotherapeuticii (CI) trial, which...